Ximelagatran

Drug Profile

Ximelagatran

Alternative Names: Exanta™; H 376; H 376/95; H 37695

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Market Withdrawal Deep vein thrombosis; Thromboembolism
  • Discontinued Postmyocardial infarction; Stroke

Most Recent Events

  • 17 Feb 2006 Clinical data from a media release have been added to the adverse events section
  • 14 Feb 2006 Discontinued - Phase-II for Postmyocardial infarction in Sweden (PO)
  • 14 Feb 2006 Discontinued - Phase-II for Postmyocardial infarction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top